<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td><hr width="200" size="1" noshade>
  </td>
</tr>
</table>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  January 20, 2006</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Exact Name of Registrant as Specified in Charter)</font></td>
</tr>
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr align="center" valign="top" bgcolor="#ffffff">
<td width="33%"><font size="2" face="serif">Delaware</font></td>
<td width="33%"><font size="2" face="serif">0-15313                </font></td>
<td width="33%"><font size="2" face="serif">13-3033811</font></td>
</tr>
<tr align="center" valign="top" bgcolor="#FFFFFF">
  <td colspan="3"><hr size="1" noshade>
    </td>
  </tr>
<tr align="center" valign="top" bgcolor="#FFFFFF">
<td><font size="2" face="serif">(State or Other Juris-<br>diction of Incorporation</font></td>
<td><font size="2" face="serif">(Commission<br>File Number)</font></td>
<td><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>
</tr>
</table>
<br><br>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br><font size="2" face="serif">East Brunswick, New Jersey 08816</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of Principal Executive Offices) (Zip Code)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">Registrant&#146;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former Name or Former Address, if Changed Since Last Report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><img src="emptybox.gif"></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><img src="emptybox.gif"></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 5.02.  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers</b></font></p>
<p align="left"><font size="2" face="serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On January 20, 2006, Clifford A. Bacsik was terminated as Vice President and Chief Accounting Officer of Savient Phamaceuticals, Inc. (the &#147;Company&#148;).</font></p>
<p align="left"><font size="2" face="serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While the Company concludes its search for a permanent replacement for Mr. Bacsik, the duties of principal accounting officer have been assumed by Gina Gutzeit.  Ms. Gutzeit has served as the Company&#146;s Interim Chief Financial Officer since October 5, 2005.  Since September 2002, Ms. Gutzeit has been a senior managing director with FTI Palladium Partners, the interim management practice of FTI Consulting, Inc., a corporate finance consulting firm. From July 2000 to August 2002, Ms. Gutzeit was a partner in the Financial Advisory Services practice of PricewaterhouseCoopers LLP.</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td align="left"><font size="2" face="serif">Date:  January 24, 2006</font></td>
  <td colspan="2" align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS,
    INC.</font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td colspan="2" align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="50%" align="left">&nbsp;</td>
<td colspan="2" align="left"><font size="2" face="serif">By: <u>/s/ Philip K. Yachmetz</u></font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td colspan="2" align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Philip K. Yachmetz</font><br>
    <font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, General Counsel</font><br>
    <font size="2" face="serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Secretary</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b411219_8k.htm", "description": "8-K", "secsgml_size_bytes": 7289}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "06546847"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  January 20, 2006
Savient Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
0-15313
13-3033811
(State or Other Juris-
diction of Incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
(b)      On January 20, 2006, Clifford A. Bacsik was terminated as Vice President and Chief Accounting Officer of Savient Phamaceuticals, Inc. (the "Company").
(c)      While the Company concludes its search for a permanent replacement for Mr. Bacsik, the duties of principal accounting officer have been assumed by Gina Gutzeit.  Ms. Gutzeit has served as the Company's Interim Chief Financial Officer since October 5, 2005.  Since September 2002, Ms. Gutzeit has been a senior managing director with FTI Palladium Partners, the interim management practice of FTI Consulting, Inc., a corporate finance consulting firm. From July 2000 to August 2002, Ms. Gutzeit was a partner in the Financial Advisory Services practice of PricewaterhouseCoopers LLP.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  January 24, 2006
SAVIENT PHARMACEUTICALS,
    INC.
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President, General Counsel
and Secretary